# Elimination drives recovery in amatoxin-induced acute liver failure

## A globally applicable management framework: preserving toxin elimination enables transplant-free recovery

Authors:

S Todd Mitchell, MD, MPH*

Dominican Hospital, Santa Cruz, CA tmitchmd@gmail.com

Daniel A Spyker, MD, PhD

Oregon Health & Science University, Portland, OR spykerfarm@gmail.com

Glenn Robbins, RPh

Dominican Hospital, Santa Cruz, CA glenn.robbins@commonspirit.org

Barry H Rumack, MD

University of Colorado School of Medicine, Aurora, CO barry.rumack@cuanschutz.edu

Corresponding Author*:

S Todd Mitchell, MD, MPH

445 Summit Rd, Watsonville, CA 95076 USA

+1-831-588-2192

email: tmitchmd@gmail.com

## ABSTRACT

Amatoxin-induced acute liver failure complicates misidentified foraged mushroom ingestion worldwide; abrupt multisystem collapse punctuates apparent improvement. Our prospective single-arm clinical trial investigated proactive toxicokinetic-based management to preserve elimination capacity: sustained enhanced hydration to maintain renal clearance; fasting plus octreotide to suppress meal-driven enterohepatic circulation; and intravenous silibinin to inhibit OATP1B3-mediated hepatic uptake, enabling safe passage and elimination of gallbladder-confined amatoxin-laden bile. Safety population (N=99) transplant-free recovery (TFR): 88.0% (87 recoveries, 6 transplants, 6 deaths). Protocol-adherent Efficacy population (n=86) TFR: 98.8% (85 recoveries, 1 transplant, 0 deaths). Multivariable analysis identified uninterrupted hydration as strongest TFR predictor (P<0.001), followed by earlier silibinin initiation (P=0.003); octreotide shortened INR recovery by 11 hours (P=0.033). These findings support a toxin elimination model in which preserved renal clearance and biliary sequestration are central recovery determinants. The kinetic balance between renal clearance and hepatic uptake governs both recovery and collapse.

ClinicalTrials.gov identifier: NCT00915681.

**INTRODUCTION**

Amatoxin mushroom poisoning presents a distinctive clinical paradox: patients typically stabilize and improve with volume replacement after presentation, yet some precipitously decline into multisystem failure hours to days later.[1,2] This unexpected transition suggests mechanisms beyond primary hepatic injury alone. While the risk of poor outcome (death, liver transplantation) is dose-related,[3] abrupt deterioration can occur after relatively small ingestions;[4] dose alone does not reliably determine outcome. This unpredictability contributes to the still considerable mortality documented in tertiary transplant centers and in the resource-limited settings where most poisonings occur. Amatoxin-induced liver injury is well characterized at the cellular level, but the determinants of recovery or collapse remain incompletely defined. In particular, the relationship between toxin elimination capacity and progression to acute liver failure (ALF) has not been prospectively evaluated. We hypothesized that impaired elimination, rather than inexorable primary hepatic injury, is the principal determinant of clinical outcome, reflecting a kinetic balance between toxin elimination and hepatic uptake.

Amatoxin inhibits RNA polymerase II, leading to transcriptional arrest and apoptosis in enterocytes, hepatocytes, and renal tubular epithelium (RTE). Thermostable, water-soluble, metabolically inert, and eliminated intact (>80% urinary recovery within 6 hours),[4–7] toxicokinetic features include rapid absorption, gastric acid and protease resistance, low distribution volume, minimal protein binding, and creatinine-like clearance.[4–7] Hepatic penetration is mediated by sinusoidal uptake via organic anion transporter polypeptide 1B3 (OATP1B3).[8] The hepatocellular fraction not bound to RNA polymerase II is excreted intact into bile, where meal-triggered enterohepatic circulation (EHC) returns toxin to the gut for renewed absorption.[7,9] A 2011 study in landrace pigs cast doubt on the mechanism's clinical

significance,[10] but methodological issues influenced the results.[11,12] A recent publication using sophisticated biochemical analysis adapted to the bile matrix found substantial amanitin content in gallbladder aspirates several days post-ingestion.[13] Like hepatic uptake, absorption (notably poor in rodents) may be transporter-facilitated;[4,14] nephrotoxicity, however, is concentration- and time-dependent.[4,15–17] Poisonings unfold in four phases: presymptomatic latency (6–24 hours); dehydrating gastrointestinal; postsymptomatic pseudo-recovery; and fulminant multisystem failure.

Silibinin dihemisuccinate (Legalon SIL, Viatris), a highly water soluble intravenous preparation derived from the common milk thistle (*Silybum marianum*),[18] inhibits sinusoidal OATP1B3-mediated hepatic uptake,[8] diverting amatoxin into the systemic circulation for glomerular filtration and urinary elimination.[18] Beagle studies and retrospective data led to European approvals long ago,[19,20] but prospective evaluation never ensued;[18] treatment failures remain unexplained.[21–24] Suppression of meal-stimulated EHC may limit post-absorption hepatic re-exposure.[25] We hypothesized that establishing proactive toxicokinetic-based management designed to preserve renal clearance and arrest EHC, pending silibinin infusion, would improve clinical outcomes.[26] Because randomized controlled trials (RCTs) for rapidly deadly poisoning antidotes are neither ethically nor practically feasible,[27,28] and building upon the unexpectedly favorable clinical outcomes in severe cases under Emergency IND authorization,[29] we undertook a prospective multicenter clinical study to evaluate the relationship between toxin elimination capacity and transplant-free recovery in amatoxin-induced acute liver failure.

## METHODS

### Human Subjects Protection

Catholic Healthcare West IRB (Santa Cruz, CA) approved the study protocol and amendments; participating hospitals obtained local IRB authorization. All participants (or parents/legal guardians for minors) provided written informed consent.

### Study Design

Prospective, multicenter, single-arm, open-label clinical study (NCT00915681). Randomization was not performed due to ethical and feasibility constraints related to disease rarity and established antidotal use. The first ten cases received silibinin under Emergency IND authorizations (January 2007–March 2009). Open IND enrollment under the multicenter study protocol ran from July 2009 through October 2017. Sample size was determined by enrollment during the study period; no formal power calculation was performed. Full protocol and Statistical Analysis Plan are provided in the Supplementary Appendix.

### Enrollment

Patients were identified through a 1-800 consultation hotline accessible via POISINDEX. Eligibility was confirmed by the coordinating investigator in consultation with the treating physician. Participating physicians agreed to protocol adherence and submission of complete inpatient medical records following hospitalization.

### Eligibility

Patients ≥2 years of age were eligible with a prespecified diagnostic triad: foraged mushroom ingestion; onset of emesis or diarrhea 6–24 hours post-ingestion; and rising transaminases. A protocol amendment excluded patients presenting with volume-unresponsive oliguric acute kidney injury (AKI). One patient <24 months of age was enrolled with parental consent.

**Pre-Enrollment Treatments**

Prior to enrollment, some patients received N-acetylcysteine (76%), activated charcoal (54%), or penicillin G (23%), at the discretion of treating physicians.

**Treatment Protocol (Santa Cruz Protocol)**

All protocol interventions were administered intravenously.

*Hydration*: Hydration targets were prespecified to maintain renal perfusion and elimination capacity. Patients received an initial crystalloid bolus of 4–7 liters, followed by maintenance infusion of D5 0.45% normal saline at ≥200 mL/hr via infusion pump. Target urine output was ≥150 mL/hr in adults and 2–3 mL/kg/hr in children. Additional fluid boluses were administered for urine output <100 mL/hr.

*Enterohepatic Circulation (EHC) Arrest:* Patients were maintained nil per os (NPO). Octreotide was administered as a continuous infusion at 50 µg/hr (n=38). Both interventions were continued until two consecutive INR measurements, 6 hours apart, demonstrated improvement.

*Silibinin:* Intravenous silibinin dihemisuccinate (Legalon SIL, Madaus GmbH/Rottapharm|Madaus) was administered as a 5 mg/kg loading dose followed by continuous infusion of 20 mg/kg/day until INR normalized (≤1.2).

**Amendments**

In 2010, physician commitment forms were introduced to ensure complete medical record recovery. In 2015, lactate monitoring was added; octreotide was incorporated to pharmacologically arrest EHC pending silibinin availability, and written treatment guidelines were distributed at enrollment.

**Data Collection**

Clinical and laboratory data were abstracted from complete inpatient medical records. Missing data were <5% for all measured variables.

**Outcomes**

The primary outcome was transplant-free recovery (survival to discharge without liver transplantation). Death and transplantation were objective events. INR values were obtained from laboratory records. Secondary outcomes included death, liver transplantation, time from silibinin initiation to first INR reduction, and hospital length of stay.

**Analysis Populations**

*Safety Population* (N=99): Patients receiving ≥1 dose of silibinin.

*Protocol-adherent (Efficacy) Population* (n=86): A protocol-adherent (Efficacy) population was defined based on adherence to key protocol components required to achieve therapeutic elimination targets, including adequate hydration and timely silibinin administration. Classification was determined from documented treatment orders and timing parameters, independent of clinical outcomes. Exclusion criteria included presentation with volume-unresponsive oliguric AKI (n=1); delayed initiation (>120 hours) or incomplete total silibinin

dose (<20 mg/kg) (n=6); or failure to achieve prespecified hydration targets (n=8). Some patients met more than one exclusion criterion.

## Statistical Analysis

Kaplan-Meier methods were used to estimate survival distributions. Multivariable logistic regression with stepwise selection (entry $P<0.10$, retention $P<0.05$) identified variables associated with transplant-free recovery. Analyses were performed using SAS-JMP. Complete case analysis was used; missing values were not imputed. Additional details are provided in the Supplementary Appendix.

## RESULTS

### Participant Flow

Of 118 patients screened, 99 met eligibility criteria and received ≥1 dose of silibinin, constituting the Safety Population. Thirteen patients were excluded from the protocol-adherent (Efficacy) population due to volume-unresponsive oliguric AKI at presentation (n=1); delayed silibinin initiation (>120 hours) or incomplete total dose (<20 mg/kg) (n=6); or failure to achieve prespecified hydration targets (n=8), with some patients meeting more than one exclusion criterion. No patients were lost to follow-up.

### Patient Characteristics

The Safety Population (N=99) was enrolled between January 2007 and October 2017, including emergency-IND (n=10), open-IND (n=87), and Health Canada Special Access (n=2) cases. Mycologic species identification was available in 15 cases.

Mean age was 52.5 years (range, 14–89); 54% were female. Median ingestion-to-presentation interval was 12 hours (IQR, 8–24); median ingestion-to-silibinin initiation interval was 48 hours (IQR, 32–72).

**Baseline Severity**

In the Safety Population, ALT exceeded 2000 U/L in 79%, and INR was ≥1.5 in 72%, ≥2.0 in 51%, and ≥4.0 in 21%. Median ingestion-to-first laboratory evaluation was 41.5 hours.

In the Efficacy Population, ALT exceeded 2000 U/L in 77%, and INR was ≥1.5 in 69%.

**Safety**

Adverse events were prospectively recorded throughout hospitalization. Treatment-emergent adverse events occurred in 24 patients (24%), totaling 29 events.

No cases of fluid overload, pulmonary edema, or heart failure occurred during protocol-specified hydration.

No serious adverse events were attributed to silibinin. Infusion reactions (warmth, flushing) occurred in 8 patients (8%) and resolved with rate adjustment.

No adverse events were attributed to octreotide (0/38).

Two patients (2%) developed acute tubular necrosis following hepatic recovery; one required temporary hemodialysis. Six deaths (6%) occurred, all attributed to hepatic failure.

**Clinical Outcomes**

*Primary—Transplant-Free Recovery:* In the ***Safety Population*** (N=99), transplant-free recovery occurred in 87 patients, liver transplantation in 6, and death in 6, corresponding to transplant-free recovery of 88.0% (95% CI, 79.8–93.6). Median hospital length of stay among survivors was 6 days. Median survival among poor-outcome patients was 179 hours (95% CI, 115–281).

In the protocol-adherent ***Efficacy Population*** (n=86), transplant-free recovery occurred in 85 patients, liver transplantation in 1, and death in 0, corresponding to transplant-free recovery of 98.8% (95% CI, 93.7–100).

**Predictors of Outcome**

In multivariable analysis, sustained hydration and shorter ingestion-to-silibinin interval were independently associated with transplant-free recovery (P<0.001 and P=0.003, respectively). Post-ingestion latency (P=0.02) and octreotide administration (P=0.03) were associated with shorter time to INR recovery. Pre-enrollment N-acetylcysteine and activated charcoal were not associated with transplant-free recovery or INR recovery.

**MELD Analysis**

Severity stratification using MELD scores demonstrated severe liver dysfunction across both protocol-adherent and non-adherent populations, with substantial overlap in severity distributions. Detailed results are provided in the Supplementary Appendix.

## DISCUSSION

In this prospective multicenter clinical trial, multisystem failure after amatoxin mushroom poisoning was associated with loss of toxin elimination capacity rather than inexorable primary hepatic injury alone. Renal clearance preservation, EHC suppression, and subsequent silibinin infusion were associated with near-universal transplant-free recovery despite severe hepatic dysfunction, while largely eliminating the expected MELD severity–outcome relationship in the protocol-adherent (Efficacy) population. These findings resolve the paradox of deterioration following apparent recovery and link elimination failure to clinical collapse. The results establish a toxicokinetic framework for both recovery and collapse in amatoxin-induced ALF.

Recent case reports from Asia, the Indian subcontinent,[30] southern Africa,[31] Oceania,[22] and the Americas[32–34] suggest an underrecognized global impact of amatoxin poisoning,[35] compounded

by documented overseas expansion of *Amanita phalloides*; its mycelia shipped undetected in the soil of potted mycorrhizal trees.[36] Because amatoxin-containing species are easily mistaken for edible mushrooms,[37] exposures recur across regions and seasons.[35] Fatal outcomes are not CDC- or WHO-reportable and attribution is not standardized, even where reporting exists; the true burden remains uncertain and likely substantially underestimated, particularly in subtropical regions where cases may be misclassified as endemic diarrheal illness.[35] These considerations underscore the need for a resource-neutral management paradigm applicable across care settings. The core protocol components—crystalloid hydration, fasting, octreotide (a WHO essential medicine), and ultrasound-guided gallbladder aspiration—require no specialized infrastructure, enabling implementation where silibinin is unavailable or logistically impractical.

Multivariable analysis identified sustained enhanced hydration as the strongest predictor of transplant-free recovery. Amatoxin is eliminated almost exclusively through glomerular filtration; renal tubular epithelial injury can develop through concentration- and time-dependent toxicity during the prolonged interval from gastrointestinal symptom onset to volume restoration.[15–17] Published clinical series consistently document oliguric AKI preceding severe hepatic deterioration,[21–24,38] while uninterrupted hydration supports renal function, preserves clearance, and improves outcomes.[16,17,39,40] In this study, patients who did not receive sustained hydration experienced substantially worse outcomes despite similar initial severity, indicating that elimination capacity, rather than ingested dose alone, strongly influences clinical trajectory. These findings support the conclusion that renal clearance preservation limits systemic toxin persistence and prevents progressive hepatocellular exposure.

Ten landrace pigs receiving LD50–LD100 α-amanitin developed acute liver failure within 42 hours; sustained hydration alone resulted in recovery in four animals and delayed multisystem

failure in the remainder.[41] Clinical series provide parallel observations. Enhanced hydration prevented oliguric AKI in Italian cohorts,[16,17,39,40] and implementation of mandatory multi-liter volume replacement at presentation in an Assamese hospital reduced mortality from 44% to 14%.[42] These findings are consistent with an elimination-dependent model in which preservation of renal clearance alters the trajectory of amatoxin poisoning and improves clinical outcomes.

Eight Efficacy-excluded patients presented with or developed persistent lactate elevation and oliguric AKI; seven had poor outcomes. One presented with severe lactate elevation and oliguria, producing no urine despite volume replacement. Another received only a single liter of volume replacement after presentation and rapidly developed persistent lactate elevation, oliguric AKI, shock, and multisystem failure prior to silibinin initiation and died on third hospital day. A similar sequence occurred in tertiary transplant centers: multiple patients developed persistent lactate elevation and oliguric AKI after IV hydration was restricted following transfer (Supplementary Appendix; Patients 1–3, 76, 188).

This pattern is clinically important because fluid restriction and early renal replacement are commonly used in other ALF etiologies to mitigate cerebral edema risk,[43] particularly in children.[44] In amatoxin poisoning, reduced renal perfusion compromises the dominant elimination pathway, promoting toxin persistence and progressive hepatic uptake.[16,17,43] Native kidneys contribute to ammonia and inflammatory mediator clearance while providing rapid elimination of most amatoxin in the systemic circulation whereas renal replacement clears ammonia and mediators incompletely[45,46] and does not achieve clinically meaningful amatoxin removal.[4–6,43] The reproducible association between hydration restriction, lactate rebound, oliguric AKI, and subsequent collapse across both resource-limited hospitals and advanced

transplant units indicates that deterioration reflects elimination failure rather than institutional capability.

This study supports a previously underrecognized role for the gallbladder as the principal reservoir of uneliminated toxin,[13,26] providing a source of repeated hepatic exposure through the physiologic bile acid recycling process known as enterohepatic circulation (EHC).[5–7,9] Hepatocytes rapidly excrete unbound amatoxin into bile,[5] which accumulates in the gallbladder.[13] Meal-induced gallbladder contraction releases this amatoxin-laden bile back into the intestine,[47] enabling renewed absorption and hepatic uptake,[5–7,9] further exacerbating hepatotoxicity before bile (and toxin) reaccumulate in the gallbladder.[47] Using biochemical analysis adapted to the bile matrix, we measured substantial amatoxin content in gallbladder aspirates from patients with amatoxin-induced ALF several days after ingestion, consistent with prolonged sequestration.[13] Augmenting fasting EHC suppression with octreotide was associated with accelerated time to INR recovery with silibinin, consistent with reducing hepatocellular exposure during the pre-silibinin interval. Together, renal clearance preservation and EHC arrest appear to slow progression to severe ALF manifestations.

The onset of shock and acidosis preceding all six deaths and four of six transplantations followed a reproducible toxicokinetic cascade associated with elimination failure (Supplementary Appendix). Precipitous multisystem failure has toxicokinetic antecedents. Rapidly absorbed, amatoxin undergoes limited first-pass hepatic uptake (<20%);[5,6] the remaining >80% enters the systemic circulation,[5,6] available for glomerular filtration without reabsorption, with most eliminated within six hours under intact perfusion.[4–7] During the presymptomatic latency, meal-triggered gallbladder contraction induces EHC;[47] renewed intestinal exposure leads to reabsorption and recurrent hepatic uptake, further exacerbating the first-pass injury.[5–7] Smaller

ingestions produce longer latency, allowing more elimination time but also more meal opportunity; larger ingestions shorten latency and reduce both.[3]

Enormous, easily underestimated isotonic gastrointestinal losses produce hypovolemia, renal hypoperfusion, and prerenal AKI—presentation hemoglobin is typically markedly elevated. The prolonged interval from symptom onset until volume resuscitation begins (>41.5 hours in this series) promotes prolonged tubular stasis, increasing renal tubular epithelial contact time and enabling concentration- and time-dependent nephrotoxicity.[4,15–17] Appropriate volume replacement reverses prerenal AKI, restores elimination, and suppresses subclinical nephrotoxic injury.[4,15–17,48] Following initial resuscitation with isotonic crystalloid, maintenance with hypotonic fluid (D5 0.45NS at approximately 200 mL/hour) provided both volume and free water support while reducing the risk of volume overload, sustaining urine output above 150 mL/hour to optimize ongoing elimination. In contrast, fluid restriction (or inadequate replacement) promotes progression from occult tubular injury to oliguric AKI, heralded by persistent lactate elevation and followed by rapid clinical deterioration.[49] Together, these observations suggest that outcome is governed by how circulating amatoxin is partitioned between renal clearance and hepatic uptake.

This study identifies a critical kinetic relationship between renal clearance and distributive hepatic uptake. Under intact perfusion, >80% of systemically circulating amatoxin—following both absorption and enterohepatic reintroduction—undergoes rapid glomerular filtration and urinary elimination, while sinusoidal OATP1B3 captures <20% of the first-pass and enterohepatic fractions. With loss of renal clearance (prerenal or oliguric), the >80% no longer cleared is instead redistributed to the liver via hepatic artery and portal vein (arteriohepatic uptake).[50] This kinetic mismatch explains how loss of clearance (oliguric AKI) can trigger the

hepatic uptake surge that precipitates multisystem failure, why even small ingestions may become lethal when elimination fails, and why risk rises the longer presentation is delayed as nephrotoxic exposure accumulates—underscoring the singular presentation exigency for rapid, generous volume replacement to restore perfusion. Renal perfusion is the principal modifiable determinant of systemic toxin clearance; maintaining it through sustained enhanced hydration prevents occult nephrotoxic injury acquired before presentation from progressing to catastrophic oliguric AKI, while allowing toxin elimination to proceed unimpeded.

Pseudo-recovery may reflect conditional toxicokinetic stability rather than an inevitable biological transition. As gastrointestinal symptoms resolve with aggressive volume replacement, restored renal elimination and biliary sequestration limit further hepatocellular exposure despite established injury. Under fasting conditions, hepatocyte-excreted amatoxin accumulates within the gallbladder, temporarily isolating toxin from both systemic circulation and the gut.[47] Sustained hydration maintains renal clearance, resolving prerenal systemic persistence and limiting progressive redistribution.[16,17] However, meal intake induces gallbladder contraction and enterohepatic circulation (EHC), returning sequestered amatoxin to the intestine for renewed absorption and hepatic exposure.[47] Fluid withdrawal or restriction permits progression of subclinical nephrotoxicity to oliguric AKI, abruptly terminating elimination capacity.[51,52] With renal clearance impaired, circulating amatoxin persists and undergoes progressive sinusoidal uptake, accelerating injury and progression to severe ALF manifestations. This sequence explains the abrupt transition from apparent clinical improvement to multisystem failure, indicating that pseudo-recovery represents a vulnerable equilibrium dependent on continued toxin elimination rather than an unpredictable interval of occult decline.

Strong association between earlier silibinin administration and transplant-free recovery supports antidotal benefit beyond hydration alone and demonstrates a therapeutic window extending to at least 120 hours post-ingestion—more than doubling previous estimates.[18,20] Serial lactate measurements provided early physiologic insight into elimination capacity: sustained lactate correction preceded recovery, whereas persistent elevation predicted treatment failure.[21,22,24,49] Hourly urine output and serial lactate measurements (every 6 hours) guided infusion rate adjustments, enabling real-time assessment of elimination capacity. Beyond its established prognostic value, serial lactate may serve as a surrogate marker for amatoxin clearance— correction reflecting restored elimination, persistent elevation signaling ongoing toxin persistence despite hemodynamic stabilization.[49] Elevated presentation lactate (2.0–8.0 mmol/L) corrected with volume replacement in 60% of patients, including eight with levels exceeding 4.0 mmol/L. These observations indicate that preservation of renal clearance permits continued toxin elimination and effective antidotal action. Conversely, treatment failures were consistently preceded by oliguric AKI,[21,22] suggesting that silibinin efficacy depends on intact renal elimination. Persistent lactate elevation (>3.0 mmol/L beyond 12–24 hours of volume optimization) despite improving creatinine and adequate urine output may identify patients in whom silibinin's renal-dependent mechanism is unlikely to succeed, prompting early transition to biliary drainage as a renal-independent elimination strategy. The lactate threshold of 3.0 mmol/L for predicting silibinin failure emerged from clinical observation rather than prospective validation; further study is needed to confirm this decision cutpoint. Together, these findings support an elimination-dependent model of silibinin effectiveness in which antidotal success requires preserved clearance.

The protocol initially relied on fasting alone to limit meal-stimulated gallbladder contraction and physiologic enterohepatic circulation (EHC) during the interval before silibinin arrival. The ≥24-hour shipping delay prompted a mid-study amendment incorporating octreotide, a World Health Organization essential medicine,[53] for its inhibitory effects on cholecystokinin-mediated gallbladder contraction and sphincter of Oddi relaxation,[54,55] thereby limiting bile delivery to the intestine.[47,53–55] After amendment incorporation, octreotide administration was associated with an 11-hour reduction in time from silibinin initiation to INR recovery, an association consistent with reduced re-exposure to biliary-excreted amatoxin during the pre-silibinin interval. This mechanism also provides context for discordant experimental observations reported by Thiel et al., in which high-dose fentanyl—known to suppress biliary motility and gastrointestinal transit—may have inadvertently reduced toxin redistribution despite differing assumptions about EHC contribution.[10] Octreotide thus serves as a pharmacological bridge, maintaining gallbladder sequestration until silibinin establishes hepatoprotection; once OATP1B3 blockade is confirmed by consecutive INR improvement, EHC-released amatoxin is safely diverted to renal elimination rather than hepatic re-uptake.

One Efficacy population–excluded patient developed oliguric AKI following transplant-unit fluid restriction yet recovered after ERCP-guided nasobiliary drain placement. When silibinin is unavailable or likely to fail (persistent lactate elevation or oliguric AKI), gallbladder drainage may provide a therapeutically rational alternative by evacuating amatoxin-containing bile.[12] Experimentally, beagles with surgical biliary diversion in place survived otherwise lethal amanitin exposure.[7,9] Recent veterinary case reports describing clinical recovery following gallbladder drainage corroborate these findings.[56,57] Biochemical confirmation of prolonged

gallbladder sequestration (described above) provides mechanistic support for drainage as a therapeutic intervention.[13,58–60]

Case reports describe durable INR improvement within 24–36 hours following gallbladder drainage procedures,[26,58–69] a recovery timeframe similar to that observed with silibinin infusion and consistent with ALF reversal when enterohepatic toxin re-entry and the resulting hepatocellular re-exposure are curtailed. Procedural risks include bile peritonitis, bleeding, and infection,[70,71] but must be weighed against the risks associated with limited elimination capacity in advanced poisoning. These reports, human and veterinary, consistently describe clinical recovery from severe amatoxin poisoning following ERCP-guided nasobiliary drainage, percutaneous or surgical cholecystostomy, and ultrasound-guided gallbladder aspiration.[26,56–69] These observations support the gallbladder as a persistent toxin reservoir and suggest biliary drainage as a globally viable method of facilitating toxin removal across treatment settings.

The treatment protocol did not incorporate N-acetylcysteine or activated charcoal; nevertheless, most patients received one or both pre-enrollment. In our cohort, neither was associated with improved transplant-free recovery nor faster INR normalization. N-acetylcysteine lacks both toxicokinetic rationale and support from animal models.[72,73] N-acetylcysteine marginally improved transplant-free survival in one non-acetaminophen ALF trial (P=.043),[74] but not in a similar pediatric study or in meta-analyses;[75,76] moreover, amatoxin poisoning patients were not represented.[21,74–76] N-acetylcysteine may transiently increase INR independent of hepatic synthetic function,[77] potentially complicating prognostic assessment.[78] Activated charcoal is frequently poorly tolerated, with recognized aspiration and ileus risk.[79–81] In amatoxin poisoning, delayed presentation, high water solubility, and rapid absorption limit meaningful adsorption.[4,5,36,37] Once systemic distribution predominates, intestinal toxin burden is expected to

be low until meal-triggered EHC during pseudo-recovery, further reducing rationale for delayed or repeated dosing. Accordingly, early volume resuscitation and sustained urine output—preserving the dominant elimination pathway—should be explicitly prioritized. In several severe cases, extensive adjunctive therapy coincided with inadequate early volume replacement, underscoring how easily elimination-critical priorities can be displaced.[82,83]

Published amatoxin series provide context but do not permit reliable benchmarking; nearly all are retrospective with heterogeneous case definitions, referral patterns, severity stratification, and transplantation practices. In contrast, this study provides the only prospective clinical data in amatoxin poisoning and demonstrates that outcomes diverged sharply with hydration adherence despite substantial severity across both populations (Supplementary Appendix: MELD stratification)—supporting management-dependent, elimination-limited collapse rather than treatment setting alone.

For comparison: pooled Western transplant-unit series report poor outcomes in 53% (n=36);[21–24] a U.S. registry (2008–2018) reported 91% survival without severity stratification or transplant differentiation (n=148);[84] worldwide pooled cases (1978–2020) showed 78% transplant-free recovery (n=877);[85] and a French series achieved 89% transplant-free recovery despite 79% receiving early silibinin (n=194).[86] Italian centers using enhanced hydration without silibinin report 80% transplant-free recovery in severe cases (ALT $\geq$2000 U/L).[36,37]

This study has limitations inherent to researching rare, rapidly fatal poisonings. Single-arm design precludes randomized comparison, and the post hoc efficacy population analysis introduced potential selection bias. Investigator involvement in protocol implementation may have influenced adherence, although outcomes were objective (death, transplantation, discharge

recovery) and ascertainment relied on primary medical records. Independent external replication has not yet been performed. Ethical and logistical constraints limit the feasibility of randomized controlled trials in amatoxin poisoning, similar to the development of other antidotal therapies.[87,88]

Protocol refinements, including incorporation of octreotide and lactate monitoring, occurred during the study period and reflected evolving mechanistic understanding. Efficacy population classification was based on contemporaneously documented treatment orders before outcome assessment rather than outcomes achieved; exclusion criteria were mechanistically defined to reflect elimination failure (e.g., restricted hydration, delayed or truncated silibinin). Interpretation must also consider the generally considerable delay between presentation and referral–enrollment, which may have influenced elimination capacity before protocol initiation. Laboratory confirmation remains unavailable; diagnosis relied on a characteristic clinical syndrome consistent with amatoxin poisoning, as mycological confirmation is unreliably available in practice. Eligibility required a prespecified diagnostic triad—foraged mushroom ingestion; emesis/diarrhea onset 6–24 hours later; and subsequently rising transaminases—supporting diagnosis when confirmatory testing was unavailable. Octreotide co-administration may complicate attribution of silibinin-specific effects; multivariable models included treatment timing and hydration status to address this. These limitations should be considered when interpreting the findings.

**CONCLUSIONS**

This prospective multicenter clinical trial of amatoxin poisoning-induced acute liver failure demonstrates that progression to multisystem failure is associated with loss of toxin elimination capacity rather than inexorable primary hepatic injury alone. The findings support a kinetic model in which preserved renal clearance and gallbladder sequestration prevent redistribution-driven surges of arteriohepatic uptake that can precipitate multisystem collapse. Preservation of renal clearance through sustained hydration, suppression of enterohepatic circulation, and subsequent silibinin administration were associated with near-universal transplant-free recovery despite severe hepatic dysfunction. These findings resolve the longstanding clinical paradox of deterioration during apparent recovery and identify elimination capacity as a central determinant of outcome.

This research establishes a kinetic relationship between renal clearance and arteriohepatic redistribution as the mechanistic basis for both recovery and collapse. Under intact perfusion, rapid glomerular filtration clears the >80% of absorbed amatoxin that escapes first-pass hepatic extraction. When native kidneys fail, this fraction redistributes to the liver via hepatic artery and portal vein with each cardiac cycle—a rate no extracorporeal modality can match. Silibinin and gallbladder drainage represent functionally equivalent interventions: both prevent hepatocellular re-exposure to sequestered amatoxin, explaining the similar recovery timeframes observed with either approach.

The results support a toxicokinetic-based management strategy prioritizing preservation of elimination pathways and prevention of meal-driven toxin re-exposure from biliary sequestration. These findings provide the first prospective evidence defining recovery determinants in amatoxin poisoning and support a globally applicable, physiologically grounded path to improving outcomes worldwide.

## DECLARATIONS

### Competing Interests

S.T.M. received consultancy fees from Rottapharm|Madaus, MEDA, and Mylan/Viatris. All other authors declare no competing interests.

### Funding

Study sponsors (Rottapharm-Madaus, Meda, and Mylan) provided investigational drug, funded shipping and provided regulatory expenses.

### Role of the funder/sponsor

Rottapharm|Madaus had a role in the original design and conduct of the study. Viatris (Mylan) reviewed and approved the manuscript for submission. The sponsors had no role in data abstraction, statistical analysis, interpretation of results, or the decision to submit for publication.

### Author contributions

Concept and design: Mitchell, Spyker, Robbins.

Acquisition, analysis, or interpretation of data: Spyker, Mitchell.

Drafting of the manuscript: Mitchell, Spyker, Robbins, Rumack.

Critical revision of the manuscript for important intellectual content: Mitchell, Spyker, Rumack.

Statistical analysis: Spyker.

Mitchell and Spyker had full access to all data and take responsibility for the integrity of the data and the accuracy of the analyses. All authors reviewed and approved the final manuscript.

**Data availability**

Data supporting the findings of this study are available in the Supplementary Materials. Additional de-identified data may be made available from the corresponding author upon reasonable request and subject to applicable institutional approvals and data-use requirements.

**Acknowledgments**

We thank the Dominican Hospital Pharmacy staff for round-the-clock storage, packing, and shipment of study drug throughout the study period. We are grateful for guidance and support from colleagues at the U.S. Food and Drug Administration, including Sandra Saniga. We also acknowledge Heinz Faulstich, Martin Langer, Larrimore Cummins, Massimo D'Amato, Joachim Maus, Michael Purzycki, Joe Veilleux, Donna Griebel Alan Buchwald, Kent Olson, Phool Konwar Deori, Jou-Fang Deng, Yuming Wang, Geng Jiawei, and Ma Xiuying. A list of treating hospitals is provided in the Supplementary Materials.

We sincerely thank the participating clinicians and hospitals where patients were managed:

Aria Health Frankford Campus. Philadelphia, PA

Arroyo Grande Community Hospital, Arroyo Grande, CA

Beth Israel Deaconess Medical Center, Boston, MA

California Pacific Medical Center, San Francisco, CA

Case Western Reserve University Hospital, Cleveland, OH

Cleveland Clinic, Cleveland, OH

Dominican Hospital, Santa Cruz, CA

Duke University Medical Center, Durham, NC

Georgetown University Hospital, Washington, DC

Georgetown University Medical Center, Washington, DC

Highland Hospital, Oakland, CA

Holy Cross Hospital, Washington, DC

Hotel-Dieu Grace Hospital, Windsor, Ontario, CANADA

Indiana University Health Medical Center, Indianapolis, IN

John Muir Health-Walnut Creek Medical Center, Walnut Creek, CA

Johns Hopkins Hospital, Baltimore, MD

Kaiser Permanente Medical Center, Roseville, CA

Kaiser Permanente Oakland, Oakland, CA

Kaiser Permanente Sacramento, Sacramento, CA

Kaiser Permanente San Jose, San Jose, CA

Kaiser Permanente Santa Rosa Medical Center, Santa Rosa, CA

Marin General Hospital. Greenbrae, CA

Morristown Medical Center, Morristown, NJ

Natividad Medical Center, Salinas, CA

Oregon Health & Science University, Portland, OR

Reston Hospital Center, Reston, VA

Royal Jubilee Hospital, Victoria, Vancouver, CANADA

Rush University Medical Center, Chicago, IL

St. Francis Hospital and Medical Center, Hartford, CT

St. Joseph Medical Center, Stockton, CA

St. Peter Hospital-Albany, Albany, NY

St. Elizabeth Youngstown Hospital, Youngstown, OH

Strong Memorial Hospital of the University of Rochester, Rochester, NY

Swedish Medical Center, Seattle, WA

Thomas Jefferson University Hospital, Philadelphia, PA

University of California, San Francisco, San Francisco, CA

University of Connecticut Health Center, Farmington, CT

University of Iowa Hospital, Iowa City, IA

University of Maryland Medical Center, Baltimore, MD

University of Medicine and Dentistry of New Jersey, Newark, NJ

University of Washington Medical Center, Seattle, WA

University Hospital, Newark, NJ

Virtua Our Lady of Lourdes Hospital, Camden, NJ

Yale New Haven Hospital, New Haven, CT.

Correspondence to: S. Todd Mitchell, MD, MPH (tmitchmd@gmail.com).

**REFERENCES**

1. Vo, K. T., Montgomery, M. E., Mitchell, S. T. et al. Amanita phalloides mushroom poisonings—Northern California, December 2016. *MMWR Morb. Mortal. Wkly. Rep.* **66**, 549–553 (2017).

2. Le Daré, B., Ferron, P. & Gicquel, T. Toxic effects of amanitins: repurposing toxicities toward new therapeutics. *Toxins* **13**, 417 (2021).

3. Escudié, L., Francoz, C., Vinel, J. P. et al. Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation. *Hepatology* **46**, 466–473 (2007).

4. Jaeger, A. Is there a role for use of elimination techniques in Amanita poisoning? *J. Toxicol. Clin. Toxicol.* **42**, 461–462 (2004).

5. Faulstich, H., Talas, A. & Wellhöner, H. H. Toxicokinetics of labeled amatoxins in the dog. *Arch. Toxicol.* **56**, 190–194 (1985).

6. Sun, J., Niu, Y. M., Zhang, Y. T. et al. Toxicity and toxicokinetics of Amanita exitialis in beagle dogs. *Toxicon* **143**, 59–67 (2018).

7. Sun, J., Zhang, Y. T., Niu, Y. M. et al. Effect of biliary drainage on the toxicity and toxicokinetics of Amanita exitialis in beagles. *Toxins* **10**, 215 (2018).

8. Letschert, K., Faulstich, H., Keller, D. & Keppler, D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. *Toxicol. Sci.* **91**, 140–149 (2006).

9. Fauser, U. & Faulstich, H. Therapy of Amanita phalloides poisoning: improvement of prognosis due to interruption of the enterohepatic circulation (common bile duct drainage). *Dtsch. Med. Wochenschr.* **98**, 2259 (1973). (In German.)

10. Thiel, C., Thiel, K., Klingert, W. et al. The enterohepatic circulation of amanitin: kinetics and therapeutical implications. *Toxicol. Lett.* **203**, 142–146 (2011).

11. Mitchell, T. Letter to the editor: regarding the Toxicology Letters publication: "The enterohepatic circulation of amanitin: kinetics and therapeutical implications (Thiel et al 2011)." *Toxicol. Lett.* **367**, 1–2 (2022).

12. Neuschwander-Tetri, B. & Scalzo, A. Comment on: amanitin intoxication. *Clin. Toxicol.* **61**, 141 (2022).

13. Leite, M., Freitas, A., Mitchell, T., Barbosa, J. & Ramos, F. Amanitin determination in bile samples by UHPLC-MS: LR-MS and HR-MS analytical performance. *J. Pharm. Biomed. Anal.* **247**, 116253 (2024).

14. Fiume, L., Derenzini, M., Marinozzi, V., Petazzi, F. & Testoni, A. Pathogenesis of gastrointestinal symptomatology during poisoning by Amanita phalloides. *Experientia* **29**, 1520–1521 (1973).

15. Marais, K., de Graaf, M., Touw, D. & Dekkers, B. Amanita poisonings: direct α-amanitin toxicity in the human kidney. Presented at the Nederlandse Ziekenhuisfarmaciedagen (Netherlands, 2024).

16. Costantino, D., Falzi, G., Langer, M. & Rivolta, E. Amanita phalloides-related nephropathy. *Contrib. Nephrol.* **10**, 84–97 (1978).

17. Vesconi, S., Langer, M., Iapichino, G., Costantino, D., Busi, C. & Fiume, L. Therapy of cytotoxic mushroom intoxication. *Crit. Care Med.* **13**, 402–406 (1985).

18. Mengs, U., Pohl, R. & Mitchell, T. Legalon SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. *Curr. Pharm. Biotechnol.* **13**, 1964–1970 (2012).

19. Vogel, G., Tuchweber, B., Trost, W. & Mengs, U. Protection by silibinin against Amanita phalloides intoxication in beagles. *Toxicol. Appl. Pharmacol.* **73**, 355–362 (1984).

20. Hruby, K., Csomos, G., Fuhrmann, M. & Thaler, H. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. *Hum. Toxicol.* **2**, 183–195 (1983).

21. Ferreira, R., Romãozinho, J. M., Amaro, P. et al. Assessment of emergency liver transplantation criteria in acute liver failure due to Amanita phalloides. *Eur. J. Gastroenterol. Hepatol.* **23**, 1226–1232 (2011).

22. Roberts, D. M., Hall, M. J., Falkland, M. M. et al. Amanita phalloides poisoning and treatment with silibinin in the Australian Capital Territory and New South Wales. *Med. J. Aust.* **198**, 43–47 (2013).

23. Fix, O. & Davern, T. Acute liver failure due to mushroom poisoning in the United States: results from the ALFSG registry. *Hepatology* **54** (Suppl 4), 497A (2011).

24. Karvellas, C., Tillman, H., Leung, A. et al. Acute liver injury and acute liver failure from mushroom poisoning in North America. *Liver Int.* **36**, 1043–1050 (2016).

25. Varekamp, J., Tan, J., Stam, J. et al. Effects of interrupting the enterohepatic circulation in amatoxin intoxications. *Clin. Toxicol.* **62**, 69–75 (2024).

26. Mitchell, T. Aggressive intravenous hydration combined with biliary drainage via cholecystostomy: a comprehensive regimen for managing amatoxin poisoning in developing country hospitals with limited resources. *Hepatology* **54** (Suppl 4), 508A (2011).

27. Isbister, G. K. & Buckley, N. A. Therapeutics in clinical toxicology: in the absence of strong evidence how do we choose between antidotes, supportive care and masterful inactivity. *Br. J. Clin. Pharmacol.* **81**, 408–411 (2016).

28. Coombs, A. Rare nature of mushroom poisoning means drug trials rarer still. *Nat. Med.* **15**, 225 (2009).

29. Mitchell, S. & Olson, K. Intravenous silibinin for the management of amatoxin poisoning: first usage in an American cohort. *Clin. Toxicol.* **46**, 396–397 (2008).

30. Jan, M., Siddiqui, T., Hamed, N. et al. Mushroom poisoning in children: clinical presentation and outcome. *J. Ayub Med. Coll. Abbottabad* **20**, 99–101 (2008).

31. Mauree, A., De Maayer, T. & Botes, A. Amanita phalloides poisoning: one harvest, three outcomes. *S. Afr. J. Surg.* **57**, 61–64 (2019).

32. Moor-Smith, M., Li, R. & Ahmad, O. The world's most poisonous mushroom, Amanita phalloides, is growing in BC. *B. C. Med. J.* **61**, 20–24 (2019).

33. Talamoni, M. et al. Intoxicación por Amanita phalloides, diagnóstico y tratamiento. *Arch. Argent. Pediatr.* **104**, 318–321 (2006). (In Spanish.)

34. Méndez-Navarro, J. et al. Hepatotoxicity from ingestion of wild mushrooms of the genus Amanita section Phalloideae collected in Mexico City: two case reports. *Ann. Hepatol.* **10**, 568–574 (2011).

35. Govorushko, S. Lower terrestrial plants (poisonous fungi). in *Natural Processes and Human Impacts: Interactions Between Humanity and the Environment* 300–302 (Springer, 2012).

36. Pringle, A. & Vellinga, E. Last chance to know? Using literature to explore the biogeography and invasion biology of the death cap mushroom Amanita phalloides. *Biol. Invasions* **8**, 1131–1144 (2006).

37. Bunyard, B. A. The real story behind increased Amanita poisonings in North America. *Fungi* **8**(3), 6–9 (2015).

38. Fineschi, V., Di Paolo, M. & Centini, F. Histological criteria for the diagnosis of Amanita phalloides poisoning. *J. Forensic Sci.* **41**, 429–432 (1996).

39. Petrolini, V., Vecchio, S., Crevani, M. et al. α-Amanitin poisoning: outcome in 242 patients treated with the Pavia mushroom protocol (N-acetylcysteine, forced diuresis and multiple-dose activated charcoal). *Clin. Toxicol.* **52**, 400 (2014).

40. Musella, G., Severgnini, P. & Assisi, F. Hepatotoxic mushroom poisoning in Northern Italy. *Clin. Toxicol.* **57**, 525–526 (2019).

41. Thiel, K., Schenk, M., Sipos, B. et al. Acute liver failure after amanitin poisoning: a porcine model to detect prognostic markers for liver regeneration. *Hepatol. Int.* **8**, 128–136 (2014).

42. Dutta, A., Das, A. K., Pegu, A. K. & Kalita, B. C. Early hydration therapy in mushroom poisoning improves mortality and morbidity. *J. Indian Soc. Toxicol.* **14**(1), 22–27 (2018).

43. Shingina, A. et al. Acute liver failure guidelines. *Am. J. Gastroenterol.* **118**, 1128–1153 (2023).

44. Squires, J. E., Alonso, E. M., Ibrahim, S. H. et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the diagnosis and management of pediatric acute liver failure. *J. Pediatr. Gastroenterol. Nutr.* **74**, 138–158 (2022).

45. Warrillow, S., Fisher, C. & Bellomo, R. Correction and control of hyperammonemia in acute liver failure: the impact of continuous renal replacement timing, intensity, and duration. *Crit. Care Med.* **48**, 218–224 (2020).

46. Lumlertgul, N. et al. Clearance of inflammatory cytokines in patients with septic acute kidney injury during renal replacement therapy using the EMiC2 filter (CLIC-AKI study). *Crit. Care* **25**, 39 (2021).

47. Okour, M. & Brundage, R. C. A gallbladder-based enterohepatic circulation model for pharmacokinetic studies. *Eur. J. Drug Metab. Pharmacokinet.* **44**, 493–504 (2019).

48. Heyman, S. N., Solomon, R. & Abassi, Z. It is not only fluids: the impact of hydration protocols used for the prevention of contrast nephropathy on renal oxygenation. *Ren. Fail.* **47**, 2528889 (2025).

49. Mitchell, T. Amatoxin mushroom poisoning (AMP): interplay of renal function, serum lactate values, IV hydration and silibinin (SIL). *Hepatol. Int.* **10** (Suppl 1), S1–S506 (2016).

50. Eipel, C., Abshagen, K. & Vollmar, B. Regulation of hepatic blood flow: the hepatic arterial buffer response. *World J. Gastroenterol.* **16**, 6046–6057 (2010).

51. Prowle, J. R., Kirwan, C. J. & Bellomo, R. Fluid management for the prevention and attenuation of acute kidney injury. *Nat. Rev. Nephrol.* **10**, 37–47 (2014).

52. Bonventre, J. V. & Yang, L. Cellular pathophysiology of ischemic acute kidney injury. *J. Clin. Invest.* **121**, 4210–4221 (2011).

53. Octreotide. *WHO Model List of Essential Medicines* 23rd edn (World Health Organization, 2023); https://list.essentialmeds.org/medicines/913.

54. Velõsy, B., Madácsy, L., Szepes, A. et al. The effects of somatostatin and octreotide on the human sphincter of Oddi. *Eur. J. Gastroenterol. Hepatol.* **11**, 897–901 (1999).

55. Jazrawi, R. P. Measurement of gallbladder motor function in health and disease. *Aliment. Pharmacol. Ther.* **14** (Suppl 2), 27–31 (2000).

56. Goupil, R., Davis, M., Kaufman, A. et al. Clinical recovery of five dogs from amatoxin mushroom poisoning using an adapted Santa Cruz protocol for humans. *J. Vet. Emerg. Crit. Care (San Antonio)* **31**, 414–427 (2021).

57. Kaae, J. A., Bever, C. S. & Poppenga, R. H. Early diagnosis of amanitin exposure (amatoxicosis) in a dog with a point-of-care diagnostic test. *J. Vet. Emerg. Crit. Care* **32**, 824–829 (2022).

58. Madhok, M., Scalzo, A., Blume, C. et al. Amanita bisporigera ingestion: mistaken identity, dose-related toxicity, and improvement despite severe hepatotoxicity. *Pediatr. Emerg. Care* **22**, 177–180 (2006).

59. Zuliani, A., Kabar, I., Mitchell, T. & Heinzow, H. Acute liver failure after ingestion of death cap mushrooms. *Dtsch. Med. Wochenschr.* **141**, 940–942 (2016). (In German.)

60. Mitchell, S. T., Deori, P. K. & Long, C. Ultrasound guided simple gallbladder aspiration for amatoxin mushroom poisoning induced hepatotoxicity and fulminant hepatic failure: an effective treatment alternative when IV silibinin is unavailable or likely to fail. Presented at the 15th Congress of the Asia Pacific Association of Medical Toxicology (Singapore, 2016).

61. Frank, I. C. & Cummins, L. Amanita poisoning treated with endoscopic biliary diversion. *J. Emerg. Nurs.* **13**, 132–136 (1987).

62. Hawkins, M. T., Paez, M., Goldberg, M. E. & Laurin, J. M. Use of intravenous silibinin and nasobiliary drainage as treatment for mushroom toxicity. *Gastroenterology* **142** (Suppl 1), S-976 (2012).

63. Dutta, A., Boruah, D. B., Mitchell, T. & Deori, P. K. Ultrasound-guided percutaneous transhepatic gallbladder aspiration (PTGBA) in the treatment of mushroom poisoning. *J. Indian Soc. Toxicol.* **14**(1), 40–44 (2018).

64. Sun, J., Zhang, H. S., Li, H. J. et al. A case study of Lepiota brunneoincarnata poisoning with endoscopic nasobiliary drainage in Shandong, China. *Toxicon* **161**, 12–16 (2019).

65. Xiuying, M., Junfeng, W., Jinbo, L. et al. Successful treatment of liver failure caused by fatal Amanita poisoning with percutaneous cholecystostomy: a case report. *Chin. J. Hepatol.* **28**, 1052–1054 (2020). (In Chinese.)

66. Bu, B., Yang, C., Ma, X. et al. A case of liver failure caused by fatal Amanita poisoning was successfully treated by open cholecystostomy drainage. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* **35**, 206–208 (2023). (In Chinese.)

67. Jobin, P., Stewart, C., Vipani, A. et al. Amanita mushroom toxin poisoning in Los Angeles County. *ACG Case Rep. J.* **11**, e01246 (2024).

68. Ma, X., Geng, J., Wang, J. et al. From coma to recovery: removal of amanitin by percutaneous transhepatic bile drainage in severe Amanita subjunquillea mushroom poisoning. *Clin. Toxicol.* **63**, 1–2 (2024).

69. Hu, K., Ndukwe, M., Vázquez-Reyes, R., Martin, L., Mitchell, T. & Kwo, P. Unexpected harvest: clinical insights from three cases of Amanita toxicity. *Am. J. Gastroenterol.* **120**, 1052 (2025).

70. Baron, T. H., Grimm, I. S. & Swanstrom, L. L. Interventional approaches to gallbladder disease. *N. Engl. J. Med.* **373**, 357–365 (2015).

71. Devane, A. M., Annam, A., Brody, L. et al. Society of Interventional Radiology quality improvement standards for percutaneous cholecystostomy and percutaneous transhepatic biliary interventions. *J. Vasc. Interv. Radiol.* **31**, 1849–1856 (2020).

72. Connors, N. J., Gosselin, S. & Hoffman, R. S. Comment on "N-acetylcysteine as a treatment for amatoxin poisoning." *Clin. Toxicol.* **59**, 534–535 (2021).

73. Schneider, S., Michelson, E. & Vanscoy, G. Failure of N-acetylcysteine to reduce α-amanitin toxicity. *J. Appl. Toxicol.* **12**, 141–142 (1992).

74. Lee, W. M., Hynan, L. S., Rossaro, L. et al. Intravenous N-acetylcysteine improves transplant-free survival in early-stage non-acetaminophen acute liver failure. *Gastroenterology* **137**, 856–864 (2009).

75. Squires, R., Dhawan, A., Alonso, E. et al. Intravenous N-acetylcysteine in pediatric patients with non-acetaminophen acute liver failure: a placebo-controlled clinical trial. *Hepatology* **57**, 1542–1549 (2013).

76. Orban, C., Agapie, M., Bratu, A. et al. No significant beneficial effects of intravenous N-acetylcysteine on patient outcome in non-paracetamol acute liver failure: a meta-analysis of randomized controlled trials. *Biomedicines* **12**, 1462 (2024).

77. Koot-Nazar, M., Kootstra-Ros, J., Mian, P., Touw, D. & Sturkenboom, M. The effect of N-acetylcysteine on the prothrombin time and international normalized ratio: a narrative review. *Clin. Toxicol.* **63**, 166–175 (2025).

78. Fernández de Larrea, C., Lozano, M., Castro, P. & Nicolás, J. Reduction in prothrombin rate caused by the administration of N-acetylcysteine in the treatment of Amanita phalloides poisoning. *Med. Clin. (Barc.)* **131**, 717–718 (2008). (In Spanish.)

79. Shannon, M. Ingestion of toxic substances by children. *N. Engl. J. Med.* **342**, 186–191 (2000).

80. Liisanantti, J., Kaukoranta, P., Martikainen, M. & Ala-Kokko, T. Aspiration pneumonia following severe self-poisoning. *Resuscitation* **56**, 49–53 (2003).

81. Longdon, P. & Henderson, A. Intestinal pseudo-obstruction following the use of enteral charcoal and sorbitol and mechanical ventilation with papaveretum sedation for theophylline poisoning. *Drug Saf.* **7**, 74–77 (1992).

82. Meltzer, M. I. Introduction to health economics for physicians. *Lancet* **358**, 993–998 (2001).

83. Taylor, D. R. & Lightbody, C. J. Futility and appropriateness: challenging words, important concepts. *Postgrad. Med. J.* **94**, 238–243 (2018).

84. De Olano, J., Wang, J., Villeneuve, E. et al. Current fatality rate of suspected cyclopeptide mushroom poisoning in the United States. *Clin. Toxicol.* **59**, 24–27 (2021).

85. Tan, J., Stam, J., van den Berg, A., van Rheenen, P., Dekkers, B. & Touw, D. Amanitin intoxication: effects of therapies on clinical outcomes—a review of 40 years of reported cases. *Clin. Toxicol. (Phila.)* **60**, 1251–1265 (2022).

86. Lecot, J., Cellier, M., Courtois, A. et al. Cyclopeptide mushroom poisoning: a retrospective series of 204 patients. *Basic Clin. Pharmacol. Toxicol.* **132**, 533–542 (2023).

87. Smilkstein, M., Knapp, G., Kulig, K. & Rumack, B. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. *N. Engl. J. Med.* **319**, 1557–1562 (1988).

88. Borron, S., Baud, F., Barriot, P., Imbert, M. & Bismuth, C. Prospective study of hydroxocobalamin for acute cyanide poisoning in smoke inhalation. *Ann. Emerg. Med.* **49**, 794–801.e2 (2007).

# Tables and Figures

**Table 1. Description of Patients by Population**

| Measure | Safety Population (n=99) | IND Population (n=87) | Efficacy Population (n=86) |
|---|---|---|---|
| Age (years)[a] | 52.5 ± 21.1<br>55 [1.58, 94] | 53.0 ± 19.8<br>55 [1.58, 94] | 53.2 ± 20.6<br>55 [6, 94] |
| Sex[bc] | F 42 (42.4%)<br>M 57 (57.6%) | F 38 (43.7%)<br>M 49 (56.3%) | F 33 (38.4%)<br>M 53 (61.6%) |
| Weight (kg)[a] | 69.4 ± 20.5<br>70.0 [9.40, 130] | 69.3 ± 21.9<br>68.6 [9.4, 130] | 70.3 ± 20.1<br>70.0 [19, 130] |
| Method of Mushroom Identification[bd] | Mycologist 15 (15.2%)<br>Patient 6 (6.06%)<br>ED Test 3 (3.03%)<br>MD 3 (3.03%)<br>PC 2 (2.02%) | Mycologist 12 (13.8%)<br>Patient 6 (6.90%)<br>ED Test 3 (3.45%)<br>MD 3 (3.45%)<br>PC 2 (2.30%) | Mycologist 14 (16.3%)<br>Patient 4 (4.65%)<br>ED Test 3 (3.49%)<br>MD 3 (3.49%)<br>PC 1 (1.16%) |
| Ingestion to Symptoms (hours)[a] | 12.8 ± 4.42 (97)<br>12 [6, 26] | 13.0 ± 4.59 (85)<br>12 [6, 26] | 12.6 ± 4.08 (84)<br>12 [6, 25.5] |
| Ingestion to First Lab (hours)[a] | 37 ± 22.7<br>41.5 [11.7, 128] | 42.7 ± 22.8<br>41.5 [11.7, 128] | 39.4 ± 19.7<br>33.7 [11.7, 83] |

[a] Reported as mean ± standard deviation (n, where missing data), median [min, max]

[b] Reported as number (%)

[c] F = female, M = male

[d] ED Test = Amatoxin test performed in the emergency department, MD = physician identification, PC = poison center identification

**Table 2. Severity and Treatment by Population**

| Measure | Safety Population (n=99) | IND Population (n=87) | Efficacy Population (n=86) |
|---|---|---|---|
| Max hemoglobin (g/dL)[a] | 15.3 ± 2.15 (95) 15.1 [10.9, 21.4] | 15.3 ± 2.21 (87) 15.1 [10.9, 21.4] | 15.2± 2.00 (82) 15.1 [11.8, 21.4] |
| Max BUN (mg/dL)[a] | 25.3 ± 14.4 (96) 21 [4, 64] | 25.2 ± 14.8 (87) 21 [4, 64] | 24.4 ± 14.0 (83) 21 [4, 64] |
| Max creatinine (mg/dL)[a] | 1.57± 1.38 (96) 1.01 [0.31, 8.83] | 1.55± 1.37 (87) 1.0 [0.31, 8.83] | 1.43± 1.33 (83) 0.98 [0.31, 8.83] |
| Max AST (U/L) Num (%) >2000[ab] | 4467± 4255 (99) 3274 [15, 19972] 66 (66.7%) | 4361 ± 3941 (87) 3291 [15, 18117] 58 (66.7%) | 4065 ± 3911 (86) 3177 [15, 18117] 55 (64%) |
| Max ALT (U/L) Number (%) >2000[a] | 4872 ± 4011 (99) 4405 [31, 27117] 78 (78.8%) | 4729 ± 3802 (87) 4405 [31, 27117] 69 (79.3%) | 4621 ± 4111 (86) 3939 [31, 27117] 66 (76.7%) |
| Max total bilirubin (mg/dL)[a] | 5.67 ± 5.28 (97) 3.32 [0.6, 25.8] | 5.50 ± 5.22 (87) 3.2 [0.6, 25.8] | 4.75 ± 4.31 (84) 3.1 [0.6, 19.6] |
| Max international normalized ratio[a] Number (%) >1.5[c] Number (%) >2 | 3.26± 3.15 (99) 2.0 [1.0, 14.9] 69 (69.7%) 47 (47.5%) | 3.24± 3.06 (87) 2.0 [1.0, 14.1] 60 (69.0%) 42 (48.3%) | 2.45 ± 1.92 (86) 1.9 [1.0, 14.9] 56 (65.1%) 35 (40.7%) |
| Max Lactate (mmol/L)[ad] | 5.00 ± 4.39 (48) 3.5 [1, 26] | 5.00 ± 4.39 (48) 3.5 [1, 26] | 3.41 ± 1.72 (37) 3.0 [1, 8] |
| MELD score[ae] Number (%) ≥40 | 24.8 ± 12.6 (96) 22.3 [6.71, 58.8] 17 (17.7%) | 24.6 ± 12.5 (87) 21.8 [6.71, 58.8] 15 (17.2%) | 21.7 ± 9.72 (83) 20.2 [6.71, 50.6] 6 (7.23%) |
| Ingestion to SIL Start (hours) [a] | 65.5 ± 23.8 (79) 63.8 [15, 150] | 64.5 ± 25.1 (87) 61.7 [15, 150] | 63.8 ± 20.3 (86) 64.4 [19, 118] |
| SIL Dose (mg/kg) [a] | 65.3 ± 36.1 (99) 61.1 [5.0, 221] | 67.0 ± 36.4 (87) 61.8 [15.0, 221] | 63.7 ± 31.3 (86) 60.7 [24.6, 182] |
| Duration of SIL Treatment (days)[af] | 2.77 ± 1.64 (99) 2.47 [0.0271, 10.5] | 2.83 ± 1.66 (87) 2.51 [0.027, 10.5] | 2.67 ± 1.39 (86) 2.46 [0.027, 8.46] |

[a] Reported as mean ± standard deviation (number), median [min, max]

[b] ALT >2000 have defined "severe" amatoxin poisoning in several retrospective series

[c] INR >1.5 is a commonly accepted threshold for defining FHF

[d] Serum lactate data were not measured on patients enrolled early in the study

[e] MELD (Model for End-Stage Liver Disease) score=3.78·ln(Bili)+11.2·ln(INR)+9.57·ln(Cr)+6.43

[f] Includes the 18-30 hours typically required to deliver SIL from shipping depots

**Table 3. Outcomes by Study Population**

| Measure | Safety Population (n=99) | IND Population (n=87) | Efficacy Population (n=86) |
|---|---|---|---|
| Outcome[ab] | Death 6 (6.06%)<br>LT   6 (6.06%)<br>TFR 87 (87.9%) | Death 5 (5.7%)<br>LT   6 (6.9%)<br>TFR 76 (87.4%) | Death 0 (0%)<br>LT 1 (1.2%)<br>TFR  85 (98.8%) |
| Outcome<br>TFR   mean<br>[95% CI][ac] | Death/LT 12 (12.1%)<br>TFR    87 (87.9%)<br>[79.8%, 93.6%] | Death/LT 11 (12.6%)<br>TFR   76 (87.4%)<br>[78.5%, 93.5%] | Death/LT 1 (1.2%)<br>TFR   85 (98.8%)<br>[93.7%, 100%] |
| TFR Hospital<br>LOS Days[de] | 6.55 ± 2.57 (87)<br>6 [3, 16] | 6.50 ± 2.63 (76)<br>6 [3, 16] | 6.48 ± 2.51 (85)<br>6 [3, 16] |

[a] reported as number (%)

[b] LT = liver transplant, TFR = Transplant-free recovery

[c] Death/LT = death or liver transplant

[d] reported as mean ± standard deviation (n), median [min, max]

[e] Hospital days = Discharge Date – Admission date + 1

## Figure 1. Subset Comparisons for Transplant-Free Recovery
Forest Plot[a] comparing the 3 study populations and 3 severity subsets of the Safety Population

| Description of Dataset | Number of Patients | | | Transplant-Free Recovery (percent) and 95% Confidence Interval |
| --- | --- | --- | --- | --- |
| | Exposed | Death /LT | TFR | |
| Safety Population | 99 | 12 | 87 | 87.9% (79.8%, 93.6%) |
| Safety subset (ALT>2000) | 78 | 11 | 67 | 85.9% (76.2%, 92.7%) |
| Safety subset (INR>1.5) | 69 | 12 | 57 | 82.6% (71.6%, 90.7%) |
| Safety subset (INR>2) | 47 | 12 | 35 | 74.5% (59.7%, 86.1%) |
| IND Population | 87 | 11 | 76 | 87.4% (78.5%, 93.5%) |
| Efficacy Population | 86 | 1 | 85 | 98.8% (93.7%, 100%) |

(Plot axis: 60 65 70 75 80 85 90 95 100)

[a] The horizontal lines (whiskers) show the 95% confidence interval on the ratio (marked with the black square). The size of the square represents the weight (size) of that subset.

## Figure 2. Multivariate Predictor of Outcome (TFR vs. Death/LT)
### Safety Population (n=99)

**Nominal Logistic Fit for Outcome-2 (TFR vs. Death/Liver transplant)**

**Effect Summary**[ab]

| Source | LogWorth | | PValue |
|---|---|---|---|
| Hydration Restricted | 8.369 | | 0.00000 |
| Ingestion to SIL treatment | 2.489 | | 0.00325 |

**Whole Model Test**

| Model | -LogLikelihood | DF | ChiSquare | Prob>ChiSq |
|---|---|---|---|---|
| Difference | 18.514387 | 2 | 37.02877 | <.0001* |
| Full | 18.049592 | | | |
| Reduced | 36.563979 | | | |

| | |
|---|---|
| RSquare (U) | 0.5064 |
| Akaike Information Criterion | 42.3518 |
| Bayesian Information Criterion | 49.8845 |
| Observations (or Sum Wgts) | 99 |

**Parameter Estimates**

| Term | Estimate | Std Error | ChiSquare | Prob>ChiSq |
|---|---|---|---|---|
| Intercept | -6.4638729 | 1.5518904 | 17.35 | <.0001* |
| Ingestion to Treatment  (hours) | 0.04561588 | 0.0161271 | 8.00 | 0.0047* |
| Hydration Restricted [1-0] | 6.06516014 | 1.4467943 | 17.57 | <.0001* |

For log odds of Death/LT/Discharge

**Effect Likelihood Ratio Tests**

| Source | Nparm | DF | L-R ChiSquare | Prob>ChiSq |
|---|---|---|---|---|
| Ingestion to SIL Treatment  (hours) | 1 | 1 | 8.66345521 | 0.0032* |
| Hydration Restricted | 1 | 1 | 34.4959057 | <.0001* |

[a] Same model was obtained for forward, backward and mixed stepwise logistic regressions. Other predictors considered: Total SIL dose (mg/kg), Age, Study maturity, NAC used, Charcoal used, Octreotide used, Bile drainage, Sex.

[b] None of the other predictors forced individually into the final model made a statistically significant contribution: e.g., charcoal (logworth 0.871, p=0.134), and NAC (logworth 1.19, p=0.065).

## Figure 3. Transplant-Free Recovery Comparisons by Study
Forest Plot[a] comparing the 4 published study populations[b] to Efficacy Population

| Country of study; Study years, Publication | Number of Patients | | | Transplant-Free Recovery (percent) and 95% Confidence Interval | |
|---|---|---|---|---|---|
| | Exposed | Death /LT | TFR | | |
| ALFSG-USA; 1998-2014 (Karvellas, 2016) | 18 | 8 | 10 | | 55.6% (30.8%, 78.5%) |
| Austrailia; 1999-2011 (Roberts, 2013) | 9 | 5 | 4 | | 44.4% (13.7%, 78.8%) |
| Coimbra; PT, 2001-11 (Ferreria, 2011) | 10 | 7 | 3 | | 30% (6.7%, 65.2%) |
| Pavia, IT; 2002-12, (Petrolini, 2014) | 50 | 10 | 40 | | 80% (66.3%, 90%) |
| US & CA; 2007-17, Efficacy Population | 86 | 1 | 85 | | 98.8% (93.7%, 100%) |
| | | | | 0    20    40    60    80    100 | |

[a] The horizontal lines (whiskers) show the 95% confidence interval on the ratio (marked with the black square). The size of the square represents the weight (size) of that subset.

[b] Review of 153 National Poison Data System fatalities from 2008-2018.[29] TFR could not be compared since transplant survivors were not identified. Our Efficacy Population included no deaths, 100% (95.8%, 100%) compared to 91.2% (85.4%, 95.2%) for their data.[29] The 95% CIs are non-overlapping.

**Table 4. Resolution of Historical Enigmas in Amatoxin Poisoning Through Toxicokinetic Mechanisms**

| Historical Enigma | Proposed Resolution |
|---|---|
| Unpredictable deterioration during apparent recovery | Pseudo-recovery reflects conditional toxicokinetic stability; meal resumption (EHC) and/or hydration restriction disrupt this equilibrium |
| Small ingestions sometimes fatal; large ingestions sometimes survived | Elimination capacity, not dose alone, determines outcome; oliguric AKI precipitates arteriohepatic redistribution |
| Oliguric AKI consistently precedes hepatic collapse | Renal perfusion loss terminates the dominant systemic elimination pathway; >80% of circulating amatoxin redistributes to the liver. |
| Silibinin failures despite early administration | Silibinin efficacy requires intact renal elimination; oliguric AKI renders hepatic protection insufficient |
| Similar recovery timeframes with silibinin or biliary drainage | Functional equivalence: both prevent hepatocellular re-exposure to sequestered amatoxin. |
| CRRT fails to substitute for native renal function | Arteriohepatic redistribution outpaces extracorporeal removal; renal replacement does not effectively remove amatoxin. |
| Transplant-unit outcomes no better than resource-limited settings | Fluid restriction practices imported from other ALF etiologies reduce renal perfusion and compromise amatoxin elimination. |

This table summarizes longstanding clinical paradoxes in amatoxin poisoning and proposed mechanistic explanations supported by this prospective trial. The unifying principle is the kinetic relationship between renal clearance and distributive arteriohepatic uptake: with preserved glomerular filtration, >80% of systemically circulating amatoxin is rapidly cleared, whereas in AKI (prerenal or oliguric) this fraction is redirected to progressive hepatic uptake. EHC, enterohepatic circulation; AKI, acute kidney injury; CRRT, continuous renal replacement therapy.